Iterum Therapeutics plc ITRM

Healthcare Biotechnology

Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. It is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase III clinical development with an oral formulation. Sulopenem is a potent, thiopenem antibiotic delivered intravenously, which is active against bacteria that belong to the group of organisms known as gram-negatives and causes urinary tract and intra-abdominal infections. It has also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.

NDAQ:ITRM - Post by User

Iterum Therapeutics plc > Iterum Therapeutics to Host Morning Conference Call on U.S.

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Oct 28, 2024 5:32am

68 Views

Post# 36284482

Iterum Therapeutics to Host Morning Conference Call on U.S.

Just In: $ITRM Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH(TM) (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract InfectionsIterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections PR Newswire Monday, October 28, 2024 , at 8:30 a.m. EDT DUBLIN and CHICAGO , ...ITRM - Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH(TM) (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features